Short answer
Axogen, Inc. (AXGN) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $70M (up 23.1% year over year) with net income of −$2M.
Q2 2026 key financials · XBRL
- Revenue
- $70M
- +23.1% YoY · +13.5% QoQ
- Net income
- −$2M
- −361.8% YoY · +92.3% QoQ
- Operating margin
- -3.1%
- Gross margin
- 72.7%
- EPS (diluted)
- −$0.02
- −300.0% YoY · +94.7% QoQ
Source: XBRL data from the Axogen, Inc. (AXGN) Q2 2026 10-Q on SEC EDGAR. USD.
Axogen, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $69,731, up 23.1% YoY from $56,662, driven by higher unit volume and pricing
- Gross margin 72.7% vs 74.2% YoY; operating margin (3.1%) vs 3.0%
- Broad-based market growth, including Extremities, Oral Maxillofacial & Head and Neck, and Breast
- Cash, equivalents and investments $111,412 vs $41,528 at December 31, 2025, following $133,252 offering proceeds
- Operating cash flow $8,786 vs $(5,449) YoY; $69,707 Credit Facility payoff and $7,000 Trace Biosciences investment
- Headwinds: macroeconomic instability, geopolitical tensions and potential trade-war disruption could cause revenue fluctuations
Risk Factors
- No material changes to risk factors disclosed in Axogen’s 2025 Form 10-K
- Investment risk: potential material harm to business, financial condition, and results
- Market risk: adverse developments could reduce common-stock trading price
- Investor loss risk: shareholders could lose part or all of their investment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axogen, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.